WSB Alert For Thursday Afternoon: Cheapest Bitcoin Miner Post COIN Public Offering - SPRT, MARA, RIOT, NCTY

COIN started trading yesterday. That's leading to the Bitcoin miners losing some steam despite Bitcoin remaining strong at over $62,000. We think that MARA, RIOT and NCTY are due for a big rebound. NCTY just raised $6.7 million at an ADS price of $24.81 to buy more Bitcoin mining machines, so the stock being under $20 is a great deal for buyers. The $20 call options expiring tomorrow offer the biggest high risk upside as well as the MARA $40 calls and RIOT $45 calls. We purchased all three call options this afternoon. A major run into the call options could cause a squeeze similar to the one we saw on GME leading into option expiry as option writers are forced to cover their position in-the-money tomorrow. 

But one miner that is falling under the radar and has the greatest upside is SPRT. It should be trading in the $10 area to come in line with the other Bitcoin mining stocks. SPRT signed a deal to merge with Greenidge, a Bitcoin miner with its own source of power. The Greenidge presentation shows how it is comparable or superior to other top publicly traded Bitcoin miners out there:


There are two articles on Seeking Alpha about this deal, both of which calculate a 2-3x upside for SPRT just to come in line with RIOT's valuation once the merger with Greenidge is complete:

https://seekingalpha.com/article/4418859-greenidge-generation-holdings-stock-minimal-downside-165-percent-upside

https://seekingalpha.com/article/4418378-support-stock-profitable-bitcoin-miner-greenidge-available-at-discount


The first article includes this chart that clearly outlines a good argument for SPRT to be in the $10 range based on RIOT's market cap of around $4 billion. 

Another stock to pay close attention to is NVCR, which rose 50% on Tuesday after the Data Monitoring Committee (DMC) recommended a reduced trial duration and patient numbers in its phase 3 trial for its Tumor Trial Fields treatment for non-small cell lung cancer. Tumor Treating Fields is a device that treats solid tumor cancers by using electro-fields to interrupt the cell division process that causes cancer to grow and spread. This is apparently working so well that the DMC said that it's unethical for patients in the control arm to continue to 18 months of follow-up and recommended a reduced sample size of 276 patients with 12 months of follow-up. It's better for these people to get the treatment rather than be part of the control group. This outstanding news means this stock is likely to be a multi-day runner and the device can probably apply to all sorts of cancers, making the potential market size in the many billions. 

Comments

Post a Comment

Popular posts from this blog

The Two Best Biotech Short Squeeze Candidates And The Next Carvana

Image
With the market having recovered most of its recent drop to be near all-time highs once again, shorts have been destroyed and are in a desperate spot. Heavily shorted stocks like B. Riley Financial, Inc. (RILY), Globe Life Inc. (GL) and Carvana Co. (CVNA) have been on absolute tears. We have written about CVNA before , as well as the impact of CVNA's move on Root , Inc. (ROOT). When a stock is squeezing like CVNA, a related stock like ROOT will follow suit. Shorts are often shorting multiple related stocks. Most don't even hide it with Kerrisdale openly bragging about its poor track record. GL was another one that was attacked by shorts which we talked about as a gamma squeeze candidate that has worked out very well over the past three weeks.  In this market of short squeezes, we have identified two excellent biotech short squeeze candidates, ImmunityBio, Inc. (IBRX) and Soleno Therapeutics, Inc. (SLNO). IBRX is starting up the production and sale of its cancer drug ANKT...
Read more

The Next NVDA-Backed Runner and New Asian IPO Squeeze Play

Image
We have seen stocks like Super Micro Computer, Inc. (SMCI) and SoundHound AI, Inc. (SOUN) have incredible squeeze runs thanks to their connection to NVIDIA Corporation (NVDA). We think the next one will be Spire Global, Inc. (SPIR), which popped a week ago after it announced a collaboration with NVDA to enhance AI-driven weather prediction. A few day later it dropped on the announcement of a financing at $14, with the potential to raise $61 million if warrants at $14.50 are exercised. We think there is a good chance that NVDA got in on this financing, as it tends to invest in the companies it does these deals with when spreading AI across different sectors. One such recent example was with Recursion Pharmaceuticals, Inc. (RXRX) for AI in drug development.  It looks like SPIR didn't really need this financing as it has enough cash and looks like it will be cash flow and net income positive in 2024. This financing was of a strategic nature, not something led by broker...
Read more

Forget about CVNA, PLCE is the Next Major Short Squeeze Play

Image
 Back in June, we called out Kerrisdale Capital and its short on Carvana Co. (CVNA) in our piece " Carvana: The Gamma Squeeze is Real, Time to Bankrupt Kerrisdale ". Kerrisdale has a history of calling one bad short after another, creating a squeeze on all of its positions as the firm and its associates face liquidity crises. Kerrisdale is once again on a cold streak as its short on Altimmune, Inc. (ALT) simultaneously blew up just as CVNA headed from $70 to $80 this week.  However, we think CVNA is done for now. Recall that in June after the initial spike to nearly $30, the stock pulled back to $20 before hitting $40 in the next month. People who are riding weekly call options aren't likely to cash in. CVNA looks headed to the mid to low $60's to close the gap that currently exists in the $62 to $66 area before resuming any further rise. Kerrisdale created an artificial short squeeze with its report, but now that both ALT and CVNA have come down from their weekly hig...
Read more